Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NASDAQ:GMTX NYSE:OGN NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.00-0.8%$6.95$5.64▼$16.76$717.52M-1.251.33 million shs780,307 shsGMTXGemini Therapeutics$66.08+1.6%$60.37$1.16▼$14.10$2.86B-0.12189,291 shs375,991 shsOGNOrganon & Co.$11.13+4.2%$9.81$8.01▼$19.05$2.90B0.64.37 million shs2.33 million shsRAREUltragenyx Pharmaceutical$29.84-0.8%$29.25$25.81▼$57.99$2.88B0.211.35 million shs1.10 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals+0.86%+3.07%-6.13%+4.75%-49.39%GMTXGemini Therapeutics-0.75%+5.80%+9.08%+27.24%+29.94%OGNOrganon & Co.+3.24%+1.09%+13.68%+5.12%-44.14%RAREUltragenyx Pharmaceutical-0.92%+5.92%+0.40%-23.77%-45.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.00-0.8%$6.95$5.64▼$16.76$717.52M-1.251.33 million shs780,307 shsGMTXGemini Therapeutics$66.08+1.6%$60.37$1.16▼$14.10$2.86B-0.12189,291 shs375,991 shsOGNOrganon & Co.$11.13+4.2%$9.81$8.01▼$19.05$2.90B0.64.37 million shs2.33 million shsRAREUltragenyx Pharmaceutical$29.84-0.8%$29.25$25.81▼$57.99$2.88B0.211.35 million shs1.10 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals+0.86%+3.07%-6.13%+4.75%-49.39%GMTXGemini Therapeutics-0.75%+5.80%+9.08%+27.24%+29.94%OGNOrganon & Co.+3.24%+1.09%+13.68%+5.12%-44.14%RAREUltragenyx Pharmaceutical-0.92%+5.92%+0.40%-23.77%-45.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.13Buy$25.29261.48% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AOGNOrganon & Co. 2.80Moderate Buy$17.3355.81% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50173.14% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, OGN, RARE, and GMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.008/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/8/2025RAREUltragenyx PharmaceuticalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $128.008/6/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.008/6/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $25.008/6/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$112.00 ➝ $105.007/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$80.007/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $34.007/14/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$65.00 ➝ $55.007/10/2025RAREUltragenyx PharmaceuticalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$88.00 ➝ $65.00(Data available from 10/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$131.16M5.46N/AN/A$4.99 per share1.40GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AOGNOrganon & Co.$6.40B0.45$5.30 per share2.10$1.83 per share6.08RAREUltragenyx Pharmaceutical$610.16M4.71N/AN/A$2.76 per share10.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AOGNOrganon & Co.$864M$2.694.142.970.9411.15%163.88%6.99%10/30/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)Latest DAWN, OGN, RARE, and GMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025DAWNDay One Biopharmaceuticals-$0.28N/AN/AN/A$38.20 millionN/A8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 million8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.72%N/A2.97%N/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ALatest DAWN, OGN, RARE, and GMTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A9.659.53GMTXGemini TherapeuticsN/A71.4971.49OGNOrganon & Co.11.981.651.13RAREUltragenyx PharmaceuticalN/A2.452.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%GMTXGemini Therapeutics75.42%OGNOrganon & Co.77.43%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%GMTXGemini Therapeutics12.90%OGNOrganon & Co.1.40%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableOGNOrganon & Co.4,000259.97 million256.33 millionNot OptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableDAWN, OGN, RARE, and GMTX HeadlinesRecent News About These CompaniesUltragenyx Pharmaceutical Inc.: Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President3 hours ago | finanznachrichten.deUltragenyx appoints Eric Olson Chief Business OfficerOctober 1 at 7:20 AM | msn.comUltragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice PresidentSeptember 30 at 4:05 PM | globenewswire.comCantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE)September 30 at 6:38 AM | msn.comRegeneron nabs FDA label expansion for Ultragenyx-partnered cholesterol drugSeptember 26, 2025 | msn.comUltragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 24, 2025 | seekingalpha.comAssenagon Asset Management S.A. Has $42.31 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 22, 2025 | marketbeat.comVoya Investment Management LLC Sells 9,125 Shares of Ultragenyx Pharmaceutical Inc. $RARESeptember 22, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Grants Restricted Stock Units to New Non-Executive OfficersSeptember 19, 2025 | quiverquant.comQUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 19, 2025 | globenewswire.comRep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) SharesSeptember 17, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 17, 2025 | marketbeat.comIs Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?September 16, 2025 | insidermonkey.comGreat Lakes Advisors LLC Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 15, 2025 | marketbeat.comMillennium Management LLC Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 14, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 2,450 SharesSeptember 13, 2025 | insidertrades.comHC Wainwright Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)September 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLCSeptember 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comCantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)September 9, 2025 | theglobeandmail.comUltragenyx Reports Positive Phase 3 Gene Therapy ResultsSeptember 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025NIO's New Dawn: Why Wall Street's Bullish Turn Signals a ComebackBy Jeffrey Neal Johnson | September 19, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025Lithium Americas Rally Lifts Other Rare Earth Stocks By Gabriel Osorio-Mazilli | September 25, 2025DAWN, OGN, RARE, and GMTX Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$7.00 -0.06 (-0.78%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Gemini Therapeutics NASDAQ:GMTX$66.08 +1.02 (+1.57%) As of 09/30/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Organon & Co. NYSE:OGN$11.12 +0.45 (+4.17%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Ultragenyx Pharmaceutical NASDAQ:RARE$29.84 -0.24 (-0.80%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Eyes New Highs, Boosted by Boeing Partnership Is Draganfly's Army Partnership a Game-Changer for Investors? Is Tilray's Stock Price Surge a Pipe Dream of Political Hype? Lithium Americas Stock Exploded Last Week—Here’s Why Is Intuitive Surgical the Hidden Winner in Healthcare’s Weakness? Marvell Soars on +$6B in Buybacks—Can the Recovery Continue? 154% Jump in Bullish Bets: Is Ford About to Hit the Gas? AppLovin Stock Momentum Builds With $800+ Analyst Price Target Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
